Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
Multiple Myeloma
DRUG: ZD6474|DRUG: VEGF-receptor tyrosine kinase (KDR)
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study